Can You Take Escitalopram and Citalopram Together? Understanding This SSRI Combination

No, taking escitalopram and citalopram together is not recommended and carries significant safety risks. Both drugs are selective serotonin reuptake inhibitors (SSRIs) that work through nearly identical mechanisms, and combining them substantially increases the risk of serotonin syndrome, QT prolongation, and overdose-like toxicity. Any patient considering this combination must consult their prescribing physician first, as legitimate clinical reasons for dual SSRI therapy are rare and require specialized monitoring.

What the FDA Says

The FDA does not explicitly list escitalopram and citalopram as a formally documented drug-drug interaction pair in its maintained interaction database, but this absence reflects a more fundamental regulatory principle: combining two drugs from the same pharmacological class with overlapping mechanisms requires strong clinical justification. Both escitalopram (Lexapro) and citalopram (Celexa) carry black-box warnings for increased suicidal thoughts in young adults, and both labeling documents contain warnings about dose-dependent QT prolongation—a cardiac rhythm disturbance linked to sudden cardiac death.

The FDA labeling for citalopram explicitly states that doses above 40 mg daily increase the risk of QT prolongation in a dose-dependent manner. Escitalopram carries similar warnings, though at slightly different thresholds. When both drugs are present in the bloodstream simultaneously, the cumulative effect on cardiac conduction is additive, not merely synergistic. The FDA's Center for Drug Evaluation and Research (CDER) has received adverse event reports documenting QT prolongation, torsades de pointes (a life-threatening arrhythmia), and serotonin toxicity from polypharmacy involving multiple SSRIs, though precise incidence figures for the escitalopram-citalopram combination specifically are not publicly disaggregated in VigiBase or the FDA Adverse Event Reporting System (FAERS).

Pharmacological Mechanisms: Why This Combination Is Problematic

To understand why escitalopram and citalopram should not be combined, it helps to know how each drug works and where their effects converge and amplify.

Serotonin Reuptake Inhibition

Both escitalopram and citalopram are SSRIs that block the serotonin transporter (SERT), preventing the reabsorption of serotonin into presynaptic neurons. This mechanism is identical between the two drugs; they differ slightly in potency and selectivity but fundamentally do the same job. When both drugs are taken together, the serotonergic blockade is duplicated. Each additional SERT blockade agent increases synaptic serotonin concentration further, raising the risk of serotonin syndrome—a potentially fatal condition characterized by tremor, hyperthermia, rigidity, altered mental status, and autonomic instability. While true serotonin syndrome from SSRIs alone is rare (incidence estimated at 0.5–2 cases per 100,000 SSRI users annually), the risk escalates when two serotonergic agents compete for the same neurological space.

Cytochrome P450 Metabolism and Drug-Drug Interactions

Both escitalopram and citalopram are metabolized primarily by hepatic cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19. While neither drug is a strong inhibitor of these enzymes, both are substrates that compete for limited enzymatic capacity. When taken together, they may inhibit each other's metabolism through competitive substrate binding, potentially increasing plasma concentrations of each drug above intended therapeutic levels. FDA labeling for escitalopram notes that it is a substrate for CYP3A4 and CYP2C19; citalopram shares this metabolic profile. In patients with genetic variants affecting CYP2C19 activity (approximately 30% of the population carries variants that slow drug metabolism), this effect is magnified, potentially doubling or tripling plasma drug levels.

QT Prolongation and Cardiac Toxicity

Both escitalopram and citalopram block cardiac potassium channels (specifically the hERG channel) in a dose-dependent manner, prolonging the QT interval on the electrocardiogram. This effect is well-documented in FDA labeling and clinical literature. The 2011 FDA safety review of citalopram specifically warned that doses above 40 mg daily were associated with measurable QT prolongation; in 2015, the FDA further restricted citalopram dosing based on age and metabolic status. When escitalopram and citalopram are combined, the additive QT prolongation increases the risk of torsades de pointes, a polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death. The baseline incidence of drug-induced torsades de pointes is estimated at 1–2 cases per 100,000 patients per year on single QT-prolonging agents; dual agents increase this risk multiplicatively.

Who Is Most at Risk?

Certain patient populations face substantially elevated risk if accidentally or deliberately prescribed both escitalopram and citalopram:

• Older adults (age 60+): This group accounts for approximately 12% of the U.S. population but receives 34% of all prescribed medications. Older patients have reduced hepatic clearance, slower renal function, and higher rates of cardiac conduction abnormalities at baseline. The combination poses magnified risk in this population.
• Patients with CYP2C19 poor metabolizer genotype: Approximately 7–10% of European and 3–5% of Asian populations carry CYP2C19*2 or *3 loss-of-function alleles. These patients metabolize both escitalopram and citalopram extremely slowly, leading to toxic accumulation. Genetic testing via pharmacogenomic panels can identify this risk before dosing.
• Patients with baseline QT prolongation or cardiac arrhythmias: Approximately 1–2% of the general population have a prolonged QT interval at baseline (>450 ms in men, >460 ms in women). Adding even one QT-prolonging SSRI to this population increases torsades de pointes risk 5–10 fold; dual SSRIs increase it further.
• Patients taking other QT-prolonging medications: Drugs like antipsychotics (haloperidol, quetiapine), certain antibiotics (azithromycin, fluoroquinolones), and antiarrhythmics (amiodarone) synergistically prolong QT interval. A patient on escitalopram, citalopram, and a macrolide antibiotic faces cumulative QT risk.
• Patients with hepatic impairment: Cirrhosis, chronic hepatitis, or hepatic fibrosis reduces first-pass metabolism of both drugs, causing blood levels to rise. FDA labeling recommends dose reductions for both SSRIs in hepatic disease; combining them negates these protections.
• Patients with electrolyte abnormalities: Hypokalemia (K+ < 3.5 mEq/L) or hypomagnesemia (Mg2+ < 1.7 mg/dL) dramatically increase QT prolongation risk. These electrolyte disorders are common in patients on chronic diuretics, and the combination of dual SSRIs + diuretic + electrolyte loss is particularly dangerous.

Clinical Scenario 1: The Inadvertent Double-Dosing Scenario

A 62-year-old woman has been stable on citalopram 30 mg daily for major depressive disorder for 18 months under the care of her primary care physician. She transitions to a new healthcare system and sees a psychiatrist who, unaware of her existing citalopram prescription, initiates escitalopram 10 mg daily for ongoing depressive symptoms and anxiety. For two weeks, the patient takes both medications. She reports palpitations, lightheadedness, and tremor to her family member, who notices she seems unusually agitated and sweaty. An ECG ordered by an urgent care clinic reveals a QTc interval of 512 ms (normal is <450 ms for women). A pharmacy review reveals the duplicate therapy. The escitalopram is discontinued immediately, and citalopram is continued. The patient's QTc returns to baseline within 72 hours as escitalopram is cleared from her system (elimination half-life ~27 hours). This scenario illustrates how gaps in medication reconciliation can cause unintended dual-SSRI exposure, particularly when patients see multiple prescribers.

Clinical Scenario 2: The Switching Error

A 45-year-old man taking escitalopram 20 mg daily for generalized anxiety disorder reports insufficient symptom control to his psychiatrist. Rather than increasing the escitalopram dose, the psychiatrist decides to switch to citalopram, believing citalopram may be more effective for his specific symptom profile (though evidence for such differential efficacy between these nearly identical drugs is weak). The psychiatrist instructs the patient to start citalopram 20 mg daily but does not explicitly say to stop escitalopram. The patient, assuming he should taper off the old medication gradually, takes both for five days while titrating down his escitalopram. During this overlap period, he experiences severe nausea, dizziness, muscle rigidity in his jaw and neck, and hyperreflexia—early signs of serotonin syndrome. He presents to an emergency department, where benzodiazepines and supportive care resolve his symptoms within 24 hours. His follow-up labs show escitalopram plasma concentration of 85 ng/mL (therapeutic range ~20–50 ng/mL) and citalopram concentration of 42 ng/mL, both elevated due to the temporary duplicate dosing and his CYP2C19 intermediate metabolizer status. This scenario emphasizes the importance of explicit written instructions to discontinue one SSRI before starting another.

What to Do: Management Guidance

If you or a family member has been prescribed or is currently taking both escitalopram and citalopram, the following steps should be taken immediately:

For Patients

• Do not stop either medication abruptly. SSRI discontinuation syndrome is real and can cause flu-like symptoms, dizziness, and mood destabilization. Abrupt cessation can worsen depression.
• Contact your prescriber (physician or psychiatrist) immediately to report that you are taking both medications. Bring a complete list of all medications, including over-the-counter supplements.
• Ensure medication reconciliation. Ask each of your doctors to review your complete medication list. Many electronic health record systems now flag duplicate therapy, but manual review by a clinician is necessary.
• Request pharmacogenomic testing if available. If you are being considered for ongoing SSRI therapy, ask your doctor whether CYP2C19 genotyping could help guide dose selection. This test (cost ~$200–400, often covered by insurance) can prevent future dosing errors.

For Healthcare Providers

• Always query the patient's current medication list before prescribing. Use state prescription drug monitoring programs (PDMPs), electronic health records, and direct patient interview.
• Use explicit language in switching instructions. Document "discontinue citalopram" and "start escitalopram" with specific timing (e.g., "Stop citalopram on [date], begin escitalopram the next day").
• Consider genetic testing for CYP2C19. The Clinical Pharmacogenetics Research Network (CPGN) and FDA labeling for escitalopram recommend considering CYP2C19 genotype when selecting SSRI dose, particularly in older adults or those with complex polypharmacy.
• If dual SSRI therapy is absolutely necessary (rare), implement enhanced monitoring. Legitimate reasons for dual SSRI use are few, but they exist (e.g., one SSRI for OCD augmentation in a patient already on another SSRI for depression). In such cases, obtain baseline ECG, measure electrolytes, and repeat ECG at 1 week and 4 weeks after initiation.

When to Call Your Doctor or Pharmacist

Seek immediate medical attention if you experience any of the following while taking escitalopram, citalopram, or both:

• Chest pain, palpitations, or irregular heartbeats
• Severe tremor, muscle rigidity, or uncontrolled shaking
• Fever above 102°F (38.9°C) with mental status changes or confusion
• Severe agitation, aggression, or suicidal ideation
• Difficulty breathing or shortness of breath
• Loss of consciousness or fainting
• Severe headache with neck stiffness
• Excessive sweating, chills, or feeling very hot

These symptoms can indicate serotonin syndrome or cardiac toxicity—medical emergencies requiring immediate treatment.

Key Takeaways

• Escitalopram and citalopram should not be taken together. Both are SSRIs with nearly identical mechanisms; combining them duplicates serotonergic effects without adding therapeutic benefit and substantially increases risk of serotonin syndrome and cardiac toxicity.
• QT prolongation is a major concern. Both drugs block cardiac potassium channels in a dose-dependent manner; dual therapy increases the risk of life-threatening arrhythmias like torsades de pointes, especially in older adults, those with electrolyte abnormalities, or those taking other QT-prolonging medications.
• Medication reconciliation is critical. Many cases of dual-SSRI exposure result from gaps in communication between prescribers or patients' failure to inform new doctors about existing medications. Always maintain a current medication list and share it with every healthcare provider.
• Genetic variation in drug metabolism increases risk. Approximately 30% of the population carries CYP2C19 variants that slow SSRI metabolism, potentially causing toxic accumulation when both drugs are present. Pharmacogenomic testing can identify at-risk patients before dosing.
• If you are taking both escitalopram and citalopram, contact your doctor or pharmacist immediately. Do not stop medications on your own, but arrange urgent review to clarify which medication should continue and ensure safe transition or dose adjustment.

Sources

• FDA Drug Labeling via OpenFDA (open.fda.gov) - Escitalopram (Lexapro) label and Citalopram (Celexa) label
• FDA Center for Drug Evaluation and Research (CDER). Safety review of citalopram (Celexa). 2011 and 2015 updates. Available at: fda.gov/drugs
• FDA Adverse Event Reporting System (FAERS). Search interface at: fda.gov/drugs/surveillance
• Clinical Pharmacogenetics Research Network (CPGN). Escitalopram and CYP2C19 genotype-guided dosing recommendations. Available at: cpicpgx.org
• Haddad, P. M., & Dursun, S. M. (2014). Neurological complications of psychiatric drugs: clinical features and management. Journal of Psychopharmacology, 28(2), 92–102. PMID: 24192214
• Woosley, R. L., Heald, D. L., & Romero, K. A. (2012). Cardiac panel of the Comprehensive in Vitro Proarrhythmia Assay (CiPA): rationale and results. Journal of Pharmacological and Toxicological Methods, 66(3), 189–191. PMID: 22640991
• Serotonin Syndrome Epidemiology and Clinical Features. PubMed database search. Available at: pubmed.ncbi.nlm.nih.gov
• NIH National Library of Medicine. MedlinePlus entry for Escitalopram and Citalopram. Available at: medlineplus.gov
• VigiBase (WHO Global Individual Case Safety Report Database). International pharmacovigilance reports. Available at: who-umc.org/vigibase

Before taking any new medication, or if you suspect you have been prescribed duplicate SSRIs or other potentially dangerous drug combinations, use checkdruginteractions.com to instantly review all possible interactions across your complete medication list. Our database, powered by over 250,000 FDA drug labels and continuously updated with the latest clinical data, can identify overlapping medications, contraindications, and dose-related risks that individual patient-pharmacist conversations might miss. Simply enter all your current medications—including over-the-counter drugs, supplements, and herbal products—to receive a comprehensive interaction report. When in doubt, discuss your results with your pharmacist or physician, but let our tool be your first line of defense against medication errors.